Fiona Simpkins, Haineng Xu, Erin Geroge, David Gallo, Sergey Medvedev, Xiaolei Wang, Rosie Kryczka, Marc Hyer, Jimmy Fourtounis, Rino Stocco, Elia Aguado-Fraile, Adam Petrone, Shou Yun Yin, Ariya Shiwram, Matthew Anderson, Hyoung Kim, Fang Liu, Gary Marshall
Ovarian cancers (OVCAs) and endometrial cancers (EMCAs) with CCNE1-amplification are often resistant to standard of care treatment and represent an unmet clinical need. Previously, synthetic-lethal screening identified loss of the CDK1 regulator, PKMYT1, as synthetically lethal with CCNE1-amplification. We hypothesized that CCNE1-amplification associated replication stress will be more effectively targeted by combining the PKMYT1 inhibitor, lunresertib (RP-6306), with the ATR inhibitor, camonsertib (RP-3500/RG6526)...
February 16, 2024: Research Square